drugset / Trial / NCT00669409

A Phase 1/2A, Single Dose Study Of PF-04383119 In Japanese Patients With Moderate To Severe Pain From Osteoarthritis Of The Knee

NCT00669409

Phase 2 Completed 83 enrolled Pfizer
RandomizedParallel-groupTriple-blindTreatment

Summary

To evaluate the safety and tolerability of single IV doses of PF-04383119 in Japanese patients with moderate to severe pain from OA of the knee (Part I). To evaluate the preliminary analgesic efficacy of PF-04383119 in Japanese patients with moderate to severe pain from OA of the knee in comparison with placebo (Part I and Part II).

Timeline

Start
2008-06-06
Primary completion
2009-12-25
Completion
2009-12-25

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tanezumab Monoclonal antibody 10 ug/kg Intravenous
Comparator Tanezumab Monoclonal antibody 25 ug/kg Intravenous
Comparator Tanezumab Monoclonal antibody 50 ug/kg Intravenous
Comparator Tanezumab Monoclonal antibody 100 ug/kg Intravenous
Comparator Tanezumab Monoclonal antibody 200 ug/kg Intravenous

Indications